CAR-T(CAR-T)细胞疗法在非肿瘤性疾病中的应用
Chimeric antigen receptor T (CAR-T) cell therapy in non-oncological diseases.
CAR-T(CAR-T)细胞在血液系统恶性肿瘤中的应用推动了这种免疫治疗形式的显著进展。
CELL INTELLIGENCE · 肿瘤细胞治疗研究
肿瘤细胞治疗研究
英文原题:What population-based databases reveal about equity in access to hematopoietic cell transplant and cellular therapy.
What population-based databases reveal about equity in access to hematopoietic cell transplant and cellular therapy.
分数与星级只用于站内排序 —— 不代表疗效、安全性或个人适用性。
没有单一数据库能充分描述细胞疗法可及性方面的差异。
基于人群的大型数据库日益用于研究造血细胞移植(HCT)和CAR-T 细胞疗法的可及性。
我们系统开展范围综述,检索2008年1月至2025年2月使用美国数据库、研究血液系统恶性肿瘤患者获得HCT或CAR-T 治疗机会的相关研究,以识别其局限并解释已报告差异的来源。
共有35项研究符合纳入标准,其中46%使用了联结数据库。不同数据来源均显示,年龄较大、种族或族裔少数群体身份、居住地社区社会经济地位较低和无私人保险,均与接受HCT和CAR-T 治疗的可能性降低相关。然而,不同数据库报告的差异程度差别很大,原因包括符合条件的人群、数据可用性以及识别治疗适合人群的能力不同。
没有单一数据库能够充分描述细胞治疗可及性方面的差异。以公平为导向的研究需要有意将研究问题与数据库优势相匹配,并加大对数据标准化和纳入健康社会决定因素的投入。
Large population-based databases are increasingly used to study access to hematopoietic cell transplantation (HCT) and chimeric antigen receptor T-cell (CAR-T) therapy.
We conducted a systematic scoping review of studies using US databases (1/2008-2/2025) to examine access to HCT or CAR-T therapy for hematologic malignancies to identify limitations and explain differences in reported disparities.
Thirty-five studies met inclusion criteria, and 46% used linked databases. Across data sources, older age, racial and ethnic minoritized status, lower neighborhood socioeconomic status, and non-private insurance were associated with lower likelihood of HCT and CAR-T receipt. However, disparities varied substantially by databases due to differences in eligible populations, data availability, and ability to identify treatment candidacy.
No single database adequately characterizes disparities in access to cellular therapies. Equity-focused research requires deliberate alignment of research questions with database strengths and greater investment in data standardization and inclusion of social determinants of health.
MEMBER ACCOUNT
登录成功会直接打开下一页。